#EULAR2022 AAV Update Reccs (1/n): 1.Tissue biopsy recommended to establish diagnosis and eval pts w/ possible relapse @rheumnow https://t.co/qsD2PPfOPU

#EULAR2022 POS0235: Filgotinib Safety in RA for Median 2.2 years: ▶️No new safety concerns from 2020 report with shorter f/u ▶️Adverse events stable, or decreased, from early studies @Rheumnow https://t.co/DO15Tqim4n

#EULAR2022 Updated Reccs for EGPA (1/n) 👉 Use high dose GC +CYP or RTX for remission induction of #EGPA @rheumnow https://t.co/2Au5UrNKs3

Secukinumab 300mg at week 52 in ankylosing spondylitis patients (who did not achieve inactive disease with SEC 150mg at week 16) experienced similar clinical response and safety profile regardless of dose escalation. #EULAR2022 @RheumNow #ABSTOP0023 https://t.co/7LeZMMWeRC

SELECT-AXIS 2 trial demonstrated efficacy and safety of upadacitinib in treatment of non-radiographic axSpA. ASAS40 at week 14 (45% vs. 23% placebo). No MACE, VTEs, IBD, death. @RheumNow #EULAR2022 ABST#OP0016 https://t.co/vyky0JJJjS

More #EULAR2022 Updated Reccs for #AAV 👉use clinical assessments & not just ANCA or CD19+ B-cell testing to inform decision for change in Rx. 👉measure Ig levels w/RTX prior to each course of RTX (to eval for immunodeficiency) 👉use PJP prophylaxis in high risk pts @rheumnow https://t.co/kYPQnLvcCK

Combination tx of NSAIDs and TNFi (celecoxib and golimumab) did not show significant superiority compared to TNFi alone in slowing radiographic progression for treatment of radiographic axSpA. There was a numerical reduction however. #EULAR2022 @RheumNow #ABSTOP0018 https://t.co/gUZAwd92dK

Household Cleaning is dirty business at least if you have #rheumatoid #arthritis as silica exposure from laundry and cleaning products were associated with RA ILD. #EULAR opening day. #ClinicalPearl #EULAR2022 @RheumNow #OP0006 https://t.co/OJQMy9Fe9m

Immune Checkpoint Inhibitor Associated Arthritis Immune checkpoint inhibitors (ICIs) have dramatically improved outcomes in numerous cancers but have been hampered by a growing spectrum of immune-related adverse events (irAEs). https://t.co/Eno0TcWlNX https://t.co/XjkBlUEFxk

#EULAR2022 RA updated reccs w/ minor changes: start MTX+GC, reduce GC rapidly, JAKi are recc only for pts w/o risk factors for CV or malignant dz (not sure I agree with this last one if the JAKi is the best drug for the pt and there are little options avail) @rheumnow https://t.co/CXyyCi6LVI